Combined treatment of invasive giant prolactinoma with surgical excision, low-dose gamma knife radiosurgery, and a dopamine agonist-Report of twocases

Tzu Chi Medical Journal

Volumn 23, Issue 4, 2011, Pages 135-138

  Loh, Tzu Wen ^a   Chiu, Tsung Lang ^a,b   Wu, Sheng Wen ^a   Hung, Hsiang Yi ^a   Chen, Kuan Pin ^a   Su, Chain Fa ^a,b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Brain neoplasm; Gamma knife; Prolactinoma; Radiosurgery

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; BLURRED VISION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CAVERNOUS SINUS; DECOMPRESSION SURGERY; DIZZINESS; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HEADACHE; HUMAN; LOW ENERGY RADIATION; MALE; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RADIATION DOSE; REMISSION; SELLA TURCICA; SURGICAL TECHNIQUE;

EID: 84855313385     PISSN: 10163190     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcmj.2011.08.003     Document Type: Article

References (26)

1. Vance M.L., Thorner M.O. Prolactinomas. Endocrinol Metab Clin North Am 1987, 16:731-753.
2. Shrivastava R.K., Arginteanu M.S., King W.A., Post K.D. Giant prolactinomas: clinical management and long-term follow up. JNeurosurg 2002, 97:299-306.
3. Corsello S.M., Ubertini G., Altomare M., Lovicu R.M., Mignec M.G., Rota C.A., et al. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf) 2003, 58:662-670.
4. Colao A., Vitale G., Cappabianca P., Briganti F., Ciccarelli A., De Rosa M., et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. JClin Endocrinol Metab 2004, 89:1704-1711.
5. Ferrari C.I., Abs R., Bevan J.S., Brabant G., Ciccarelli E., Motta T., et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 1997, 46:409-413.
6. Colao A., Di Sarno A., Landi M.L., Cirillo S., Sarnacchiaro F., Facciolli G., et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. JClin Endocrinol Metab 1997, 82:3574-3579.
7. Biller B.M., Molitch M.E., Vance M.L., Cannistraro K.B., Davis K.R., Simons J.A., et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. JClin Endocrinol Metab 1996, 81:2338-2343.
8. Verhelst J., Abs R., Maiter D., Van den Bruel A., Vandeweghe M., Velkeniers B., et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. JClin Endocrinol Metab 1999, 84:2518-2522.
9. Shimon I., Benbassat C., Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007, 156:225-231.
10. Yu C., Wu Z., Gong J. Combined treatment of invasive giant prolactinomas. Pituitary 2005, 8:61-65.
11. Knosp E., Steiner E., Kitz K., Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993, 33:610-618.
12. Ciccarelli A., Daly A.F., Beckers A. The epidemiology of prolactinomas. Pituitary 2005, 8:3-6.
13. Schlechte J., Dolan K., Sherman B., Chapler F., Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. JClin Endocrinol Metab 1989, 68:412-418.
14. Weiss M.H., Teal J., Gott P., Wycoff R., Yadley R., Apuzzo M.L., et al. Natural history of microprolactinomas: six-year follow-up. Neurosurgery 1983, 12:180-183.
15. Weiss M.H., Wycoff R.R., Yadley R., Gott P., Feldon S. Bromocriptine treatment of prolactin-secreting tumors: surgical implications. Neurosurgery 1983, 12:640-642.
16. Turner H.E., Wass J.A. Are markers of proliferation valuable in the histological assessment of pituitary tumours?. Pituitary 1999, 1:147-151.
17. Pernicone P.J., Scheithauer B.W., Sebo T.J., Kovacs K.T., Horvath E., Young W.F., et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 1997, 79:804-812.
18. Pouratian N., Sheehan J., Jagannathan J., Laws E.R., Steiner L., Vance M.L. Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 2006, 59:255-266.
19. Landolt A.M., Lomax N. Gamma knife radiosurgery for prolactinomas. JNeurosurg 2000, 93(Suppl. 3):14-18.
20. Lim Y.L., Leem W., Kim T.S., Rhee B.A., Kim G.K. Four years' experiences in the treatment of pituitary adenomas with gamma knife radiosurgery. Stereotact Funct Neurosurg 1998, 70(Suppl. 1):95-109.
21. Stafford S.L., Pollock B.E., Leavitt J.A., Foote R.L., Brown P.D., Link M.J., et al. Astudy on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2003, 55:1177-1181.
22. Leber K.A., Bergloff J., Pendl G. Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. JNeurosurg 1998, 88:43-50.
23. Girkin C.A., Comey C.H., Lunsford L.D., Goodman M.L., Kline L.B. Radiation optic neuropathy after stereotactic radiosurgery. Ophthalmology 1997, 104:1634-1643.
24. Laws E.R., Vance M.L. Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg Clin N Am 1999, 10:327-336.
25. Ove R., Kelman S., Amin P.P., Chin L.S. Preservation of visual fields after peri-sellar gamma-knife radiosurgery. Int J Cancer 2000, 90:343-350.
26. Tishler R.B., Loeffler J.S., Lunsford L.D., Duma C., Alexander E., Kooy H.M., et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993, 27:215-221.